PF-06409577 is a direct AMPK activator out of a Pfizer diabetic nephropathy programme, and CAS 1467057-23-3 identifies it. Direct is the operative word: it binds the kinase itself rather than nudging energy charge and hoping AMPK notices.
The PF-06409577 chemical structure is based on a 6-chloroindole-3-carboxylic acid scaffold carrying a phenyl ring at C5 that terminates in a 1-hydroxycyclobutyl group. The PF-06409577 molecular weight is 341.79 g/mol, with the molecular formula C19H16ClNO3 and a calculated logP near 4.4.
Application of PF-06409577
Anyone studying AMPK meets the same problem: the classic tools do not activate it cleanly. Metformin works through complex I, so any effect could be mitochondrial. AICAR must be phosphorylated to ZMP, perturbing other AMP-sensitive enzymes. Neither lets you pin the phenotype on AMPK.
This one does, because it binds the kinase itself. Against A-769662, the earlier beta1-selective tool, it is more potent and orally viable in rats, dogs and monkeys, moving the chemotype into animals.
The constraint is the isoform, and it catches people out. Beta1 dominates the liver; skeletal muscle runs mostly on beta2. Point this compound at a muscle question and it looks inert: not a failed experiment, the wrong probe.
One more trap. The acyl glucuronides of this molecule are themselves direct AMPK activators, so metabolism does not switch the pharmacology off. A model tracking only parent understates active material, and dose-response curves can sit left of where parent concentrations predict.
In Vitro
Potency is nearly identical across both beta1-containing complexes: 7.0 nM for alpha1beta1gamma1 and 6.8 nM for alpha2beta1gamma1, human and rat enzymes behaving alike. Beta2-containing complexes need thousands of nanomolar, a window of three orders of magnitude. The off-target picture is quiet: broad panels of receptors, channels and kinases show little, and PF-06409577 spares hERG and the major cytochrome P450s at 100 micromolar.
In Vivo
Pfizer PF-06409577 was built for the kidney, and rats with diabetic nephropathy show better renal function and less proteinuria. The liver responds too: 100 mg/kg orally in mice gives maximal suppression of de novo lipogenesis at serum levels near 8 nM, matching cell-free potency, and mice and primates show lower hepatic steatosis and serum cholesterol. A later result widened the picture: in atherosclerotic mice it cut plaque burden through myeloid beta1 rather than lipid lowering, implicating macrophages, not hepatocytes.
Biochemical and Physiological Actions
The PF-06409577 structure occupies the allosteric drug and metabolite site, where the beta carbohydrate-binding module meets the N-lobe of the alpha kinase domain. The PF-06409577 molecular structure supports selective binding at this allosteric site, contributing to its preference for beta1-containing AMPK complexes. Sequence differences between beta1 and beta2 line that pocket, so the isoform preference is designed rather than accidental.
Activation switches the kinase into energy-conservation mode: acetyl-CoA carboxylase gets phosphorylated, fatty acid and cholesterol synthesis stalls and lipogenic readouts move first.
Features and Benefits of PF-06409577
PF-06409577 fits a specific job:
- Single-digit nanomolar activation with a wide beta1 over beta2 margin.
- Direct binding, so effects attribute to AMPK, not to energy stress.
- Oral exposure enough for animal work, unlike earlier beta1 tools.
- A clean hERG and cytochrome P450 profile.
Powered by Bioz